Konstellate has introduced its new platform that synthesizes KOL discussions across multiple digital formats to provide pharmaceutical companies with unparalleled insights never before available.

The AI-powered platform, with the ability to track and summarize KOL discussions, solves one of the biggest pain points that is frequently experienced in healthcare decision-making - fragmented insights from KOLs across articles, podcasts, and videos.

It uniquely features OLI, an Opinion Leader Intelligence chatbot, that users can instantly query and receive real-time answers across all KOL content, enabling faster decision-making and deeper engagement with expert discussions.

As a result, leading pharmaceutical companies that were early adopters of Konstellate have reported significant improvements in strategic decision-making by substantially improving their ability to derive actionable insights directly from KOLs digital content.

"What makes Konstellate exciting is that it bridges the digital insight gap for pharma companies that have traditionally struggled to track and analyze their KOL insights efficiently. Pharma marketers can now not only extract insights from in-person engagements, but also from what physicians are saying publicly as well. Our platform uses AI capabilities to empower pharma companies with a real-time, structured view of expert discussions across all formats. Our real-world user feedback has been overwhelmingly positive and we look forward to assisting more pharmaceutical companies with KOL intelligence as we expand our customer base," said Sam Bahreini, Founder & CEO of Konstellate.

Pharmaceutical companies rely on KOLs to guide clinical strategies, market trends, and regulatory landscapes, but they often face challenges in aggregating and structuring this vast amount of content efficiently.

Since launching, Konstellate has rapidly gained traction among leading pharmaceutical companies, providing them with AI-powered insights to optimize decision-making across multiple departments, including marketing, medical affairs, thought leader engagement, and market access teams.